Sionna Therapeutics (SION) Competitors $24.39 +0.65 (+2.74%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SION vs. MLTX, APLS, PTGX, MIRM, INDV, MTSR, SRRK, MENS, KYMR, and AMRXShould you be buying Sionna Therapeutics stock or one of its competitors? The main competitors of Sionna Therapeutics include MoonLake Immunotherapeutics (MLTX), Apellis Pharmaceuticals (APLS), Protagonist Therapeutics (PTGX), Mirum Pharmaceuticals (MIRM), Indivior (INDV), Metsera (MTSR), Scholar Rock (SRRK), Jyong Biotech (MENS), Kymera Therapeutics (KYMR), and Amneal Pharmaceuticals (AMRX). These companies are all part of the "pharmaceutical products" industry. Sionna Therapeutics vs. Its Competitors MoonLake Immunotherapeutics Apellis Pharmaceuticals Protagonist Therapeutics Mirum Pharmaceuticals Indivior Metsera Scholar Rock Jyong Biotech Kymera Therapeutics Amneal Pharmaceuticals Sionna Therapeutics (NASDAQ:SION) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation. Does the media favor SION or MLTX? In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 5 mentions for MoonLake Immunotherapeutics and 2 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 0.83 beat MoonLake Immunotherapeutics' score of 0.37 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend SION or MLTX? Sionna Therapeutics currently has a consensus target price of $38.50, indicating a potential upside of 57.85%. MoonLake Immunotherapeutics has a consensus target price of $74.43, indicating a potential upside of 33.17%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Sionna Therapeutics is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00MoonLake Immunotherapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has higher valuation & earnings, SION or MLTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/A-$61.69MN/AN/AMoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.78-20.10 Do insiders & institutionals believe in SION or MLTX? 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 3.9% of Sionna Therapeutics shares are owned by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is SION or MLTX more profitable? Sionna Therapeutics' return on equity of 0.00% beat MoonLake Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A MoonLake Immunotherapeutics N/A -40.98%-35.81% SummarySionna Therapeutics beats MoonLake Immunotherapeutics on 6 of the 10 factors compared between the two stocks. Get Sionna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SION and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SION and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SION vs. The Competition Export to ExcelMetricSionna TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.08B$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E RatioN/A21.0031.3626.05Price / SalesN/A209.44387.8788.42Price / CashN/A44.5038.0259.36Price / Book3.208.129.536.60Net Income-$61.69M-$54.72M$3.26B$265.65M7 Day Performance17.15%2.62%2.14%2.00%1 Month Performance27.43%3.25%3.22%0.46%1 Year PerformanceN/A10.82%30.18%18.88% Sionna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SIONSionna Therapeutics1.8754 of 5 stars$24.39+2.7%$38.50+57.9%N/A$1.08BN/A0.0035News CoverageMLTXMoonLake Immunotherapeutics1.6313 of 5 stars$54.88-1.4%$74.43+35.6%+12.3%$3.51BN/A-19.742APLSApellis Pharmaceuticals4.2476 of 5 stars$27.62+3.9%$34.12+23.5%-30.3%$3.49B$781.37M-15.18770News CoverageInsider TradeShort Interest ↑PTGXProtagonist Therapeutics1.9542 of 5 stars$54.99-3.1%$67.20+22.2%+37.9%$3.42B$434.43M78.56120Positive NewsMIRMMirum Pharmaceuticals3.4922 of 5 stars$64.83-0.5%$74.13+14.3%+73.9%$3.26B$429.16M-53.58140News CoveragePositive NewsINDVIndivior1.706 of 5 stars$23.17+0.9%$19.60-15.4%+97.7%$3.19B$1.17B37.371,051Positive NewsMTSRMetseraN/A$30.30-1.8%$55.00+81.5%N/A$3.18BN/A0.0081News CoveragePositive NewsSRRKScholar Rock4.5806 of 5 stars$32.29+1.0%$45.14+39.8%+282.8%$3.10B$33.19M-11.10140News CoveragePositive NewsAnalyst ForecastMENSJyong BiotechN/A$39.59+7.3%N/AN/A$3.01BN/A0.0031News CoverageKYMRKymera Therapeutics2.7175 of 5 stars$41.55+2.0%$59.11+42.3%-7.7%$2.97B$47.07M-11.97170AMRXAmneal Pharmaceuticals3.3271 of 5 stars$9.39-0.1%$11.60+23.5%+14.4%$2.94B$2.79B939.948,100News CoveragePositive NewsInsider Trade Related Companies and Tools Related Companies MLTX Alternatives APLS Alternatives PTGX Alternatives MIRM Alternatives INDV Alternatives MTSR Alternatives SRRK Alternatives MENS Alternatives KYMR Alternatives AMRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SION) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sionna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sionna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access